News and Events

Replimune Announces First Patients Dosed In A Phase 1/2 Clinical Trial Of Its RP1 Oncolytic Immunotherapy In Patients With Advanced Solid Tumors

– Woburn, MA, November 14, 2017

Switching On
the Immune System
To Fight Cancer

Cancer is one of the most difficult diseases to treat. It is constantly changing, requiring new and more sophisticated therapies.

Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, generating a powerful patient-specific, systemic immune response.

Oncolytic immunotherapy enhances the effectiveness of immune checkpoint blockade and is expected to become the second cornerstone of immuno-oncology (IO) approaches, moving beyond incremental improvements in cancer treatment to help more patients overcome their disease.

Our Immulytic™ Platform

The “On-Switch” for
Immuno-Oncology

Novel Therapeutics

Rapidly Advancing
Clinical Programs

Experienced Team

Pioneers in Oncolytic
Immunotherapy